Definium Therapeutics, Inc. (DFTX)
Nasdaq: DFTX · Medicinal Chemicals & Botanical Products · New York, NY · filing with the SEC since 2020
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Report filed | Feb 26, 2026 | Mar 6, 2025 | Feb 28, 2024 | Mar 9, 2023 | Mar 28, 2022 | · | · |
| For lenders | |||||||
| Net interest income | · | · | 4,664 | 1,495 | -359 | -164 | · |
| Research and development | 117,665 | 65,297 | 52,124 | 36,169 | 34,789 | 18,631 | · |
| General and administrative | 48,644 | 38,619 | 41,742 | 30,162 | 59,065 | 14,399 | · |
| Total operating expenses | 166,309 | 103,916 | 93,866 | 66,331 | 93,854 | 33,030 | · |
| Operating income | -166,309 | -103,916 | -93,866 | -66,331 | -93,854 | -33,030 | · |
| Interest expense | 5,482 | 2,283 | 920 | · | · | · | · |
| Interest and investment income | 10,960 | 11,558 | 5,584 | · | · | · | · |
| Other income (expense), net | -17,484 | -4,763 | -1,866 | 9,535 | -339 | -907 | · |
| Income before income taxes | -183,793 | -108,679 | -95,732 | -56,796 | -94,193 | -33,937 | -10,699 |
| Income tax expense | 0 | · | · | · | -1,157 | · | · |
| Net income including non-controlling interests | -183,793 | -108,679 | -95,732 | -56,796 | -93,036 | -33,937 | · |
| Net income | -183,793 | -108,679 | -95,732 | -56,796 | -93,036 | -33,937 | · |
| Net income to common shareholders | -183,793 | -108,679 | · | · | · | · | · |
| Earnings per share, basic | -2.06 | -1.54 | -2.44 | -1.84 | -3.40 | · | · |
| Earnings per share, diluted | -2.06 | -1.54 | -2.44 | -1.84 | -3.40 | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -0.23 | -0.13 | · |
| Weighted average shares, basic | 89,327,608 | 70,461,067 | 39,157,420 | 30,857,463 | 27,377,082 | · | · |
| Weighted average shares, diluted | 89,327,608 | 70,461,067 | 39,157,420 | 30,857,463 | 27,377,082 | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 410,656,231 | 266,220,592 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Net interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestAndDividendOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted